+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Candidiasis Drugs Market 2019-2023 - Product Image

Global Candidiasis Drugs Market 2019-2023

  • ID: 4749674
  • Report
  • January 2019
  • Region: Global
  • 124 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Astellas Pharma
  • Bayer
  • Fresenius
  • Merck
  • Pfizer
  • MORE
Advances in diagnosis of antifungal resistant pathogens to drive market growth. Although the currently available antifungal drugs are killing various species of candidiasis, some fungi can develop the ability to defend these drugs. For instance, Candida auris, an emerging antifungal-resistant yeast, is frequently resistant to multiple antifungal drugs that were used to treat Candida infections. Moreover, it can cause serious bloodstream infections in hospitalized patients. Hence, advanced technologies are required for the diagnosis of such fungal diseases caused by antifungal-resistant pathogens. The analysts have predicted that the candidiasis drugs market will register a CAGR of almost 4% by 2023.

Market Overview

Rising awareness about candidiasis

The signs and symptoms of candidiasis are very broad, and they also depend on the type of candidiasis infection. They sometimes resemble the symptoms of other diseases caused by bacteria. Hence, confirmatory diagnosis methods are required to confirm the disease after assessing the initial symptoms. Early detection can aid in treating them more effectively. Therefore, to create awareness about the disease and treatment options and avoid delay in diagnosis, the CDC is providing information about candidiasis, and its causes, risk factors, transmission, diagnosis, and treatment in the US.
Side effects of available drugs

Although several off-label medications are available for the symptomatic treatment of candidiasis, the side effects associated with them are decreasing their preference. For instance, polyene antifungal medicine, nystatin causes mouth irritation, diarrhea, nausea, vomiting, stomach upset, rashes, hives, and skin irritation. Although azole medications such as fluconazole, voriconazole, and miconazole are usually well tolerated, they cause side effects such as a headache, nausea, abdominal pain, diarrhea, vomiting, dyspepsia, liver damages, and rashes.

For the detailed list of factors that will drive and challenge the growth of the candidiasis drugs market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Merck and Pfizer, the competitive environment is quite intense. Factors such as the advances in diagnosis of antifungal resistant pathogens and the rising awareness about candidiasis, will provide considerable growth opportunities to candidiasis drugs manufacturers. Astellas Pharma, Bayer, Fresenius, Merck, and Pfizer are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Astellas Pharma
  • Bayer
  • Fresenius
  • Merck
  • Pfizer
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Azoles - Market size and forecast 2018-2023
  • Echinocandins - Market size and forecast 2018-2023
  • Other drugs - Market size and forecast 2018-2023
  • Market opportunity by type
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 12: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Astellas Pharma
  • Bayer
  • Fresenius
  • Merck
  • Pfizer
PART 13: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Years in consideration
Exhibit 02: Global infectious disease treatment market
Exhibit 03: Segments of global infectious disease treatment market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Azoles - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Azoles - Year-over-year growth 2019-2023 (%)
Exhibit 22: Echinocandins - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Echinocandins - Year-over-year growth 2019-2023 (%)
Exhibit 24: Other drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Other drugs - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by type
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Decision framework
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: Astellas Pharma - Vendor overview
Exhibit 52: Astellas Pharma - Business segments
Exhibit 53: Astellas Pharma - Organizational developments
Exhibit 54: Astellas Pharma - Geographic focus
Exhibit 55: Astellas Pharma - Key offerings
Exhibit 56: Astellas Pharma - Key customers
Exhibit 57: Bayer - Vendor overview
Exhibit 58: Bayer - Business segments
Exhibit 59: Bayer - Organizational developments
Exhibit 60: Bayer - Geographic focus
Exhibit 61: Bayer - Segment focus
Exhibit 62: Bayer - Key offerings
Exhibit 63: Bayer - Key customers
Exhibit 64: Fresenius - Vendor overview
Exhibit 65: Fresenius - Business segments
Exhibit 66: Fresenius - Organizational developments
Exhibit 67: Fresenius - Geographic focus
Exhibit 68: Fresenius - Segment focus
Exhibit 69: Fresenius - Key offerings
Exhibit 70: Fresenius - Key customers
Exhibit 71: Merck - Vendor overview
Exhibit 72: Merck - Business segments
Exhibit 73: Merck - Organizational developments
Exhibit 74: Merck - Geographic focus
Exhibit 75: Merck - Segment focus
Exhibit 76: Merck - Key offerings
Exhibit 77: Merck - Key customers
Exhibit 78: Pfizer - Vendor overview
Exhibit 79: Pfizer - Business segments
Exhibit 80: Pfizer - Organizational developments
Exhibit 81: Pfizer - Geographic focus
Exhibit 82: Pfizer - Segment focus
Exhibit 83: Pfizer - Key offerings
Exhibit 84: Pfizer - Key customers
Exhibit 85: Validation techniques employed for market sizing
Exhibit 86: List of abbreviations
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Astellas Pharma
  • Bayer
  • Fresenius
  • Merck
  • Pfizer
  • MORE
Global Candidiasis Drugs Market 2019-2023

The analyst recognizes the following companies as the key players in the global candidiasis drugs market: Astellas Pharma, Bayer, Fresenius, Merck, and Pfizer.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the advances in diagnosis of antifungal resistant pathogens.”

According to the report, one of the major drivers for this market is the rising awareness about candidiasis.

Further, the report states that one of the major factors hindering the growth of this market is the side effects of available drugs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Astellas Pharma
  • Bayer
  • Fresenius
  • Merck
  • Pfizer
Note: Product cover images may vary from those shown
Adroll
adroll